Krystal Biotech Inc.
NASDAQ · KRYS·Pittsburgh, PA·Mid-cap·Approved
Redosable gene therapy company with Vyjuvek (beremagene geperpavec) approved as the first topical gene therapy for dystrophic epidermolysis bullosa. Krystal's platform uses non-integrating HSV-1 vectors with pipeline programs in cystic fibrosis and aesthetic dermatology.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Krystal Biotech Corporate Presentation May 2026 | Corporate overview | May 1, 2026 | 51 | — |